IMO the company should just forge ahead with the 210 program. It's got so much potential. Changing Directors isn't going to add shareholder value the way success with 210 will. But, in the meantime, we'll be buying even more now, Malmanu. I'd have to say the unnecessary distraction from the main game of drug development is opening up some good buying opportunities.
Enjoy the Easter break.
Ann: Notice Under Section 203D, page-35
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)